GI
DSGN icon

GAMMA Investing’s Design Therapeutics DSGN Stock Holding History

GAMMA Investing’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21K Sell
1,450
-22
-1% -$274 ﹤0.01% 2813
2026
Q1 		$15.7K Buy
1,472
+722
+96% +$7.3K ﹤0.01% 2850
2025
Q4 		$7.04K Buy
750
+307
+69% +$2.4K ﹤0.01% 3132
2025
Q3 		$3.34K Buy
+443
New +$2.22K ﹤0.01% 3318
2025
Q2 		– Sell
-228
Closed -$880 – 3809
2025
Q1 		$880 Sell
228
-842
-79% -$4.02K ﹤0.01% 3582
2024
Q4 		$6.6K Buy
1,070
+653
+157% +$3.78K ﹤0.01% 2793
2024
Q3 		$2.24K Buy
+417
New +$1.96K ﹤0.01% 3034

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GAMMA Investing's DSGN Position: Q2 2026 in Review

GAMMA Investing reduced its Design Therapeutics (DSGN) stake by 1.5% in Q2 2026, selling an estimated $274 and leaving 1,450 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #2813.

GAMMA Investing first reported a position in DSGN in Q3 2024 and has held it in 7 quarters since. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • GAMMA Investing held 1,450 shares of Design Therapeutics worth $21K as of Q2 2026.
  • GAMMA Investing sold 22 Design Therapeutics shares in Q2 2026, an estimated $274.
  • Design Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #2813 holding.
  • GAMMA Investing first reported a position in Design Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.